Updated classification and novel treatment prospective for nodal peripheral T-cell lymphomas [0.03%]
淋巴结外T细胞淋巴瘤的最新分型和治疗展望
Pier Paolo Piccaluga
Pier Paolo Piccaluga
Targeted therapies in the treatment of adult acute myeloid leukemias: current status and future perspectives [0.03%]
急性髓系白血病的靶向治疗：现状和未来展望
Germana Castelli,Elvira Pelosi,Ugo Testa
Germana Castelli
The rapid advancement of next-generation sequencing techniques and the identification of molecular driver events responsible for leukemia development are opening the door to new pharmacologic-targeted agents to tailor treatment of acute mye...
Potential role for all- trans retinoic acid in nonpromyelocytic acute myeloid leukemia [0.03%]
全反式维甲酸在非 promyelocytic 麻疹样细胞白血病中的潜在作用
Hayley S Ma,Tara M Robinson,Donald Small
Hayley S Ma
All-trans retinoic acid (ATRA) has been very successful in the subtype of acute myelogenous leukemia known as acute promyelocytic leukemia due to targeted reactivation of retinoic acid signaling. There has been great interest in applying th...
Are FLT3 inhibitors likely to improve FLT3-mutated acute myeloid leukemia in the foreseeable future? [0.03%]
FLT3抑制剂有望在近期改善急性髓系白血病FLT3突变吗？
Sabine Kayser,Mark J Levis
Sabine Kayser
Sebastian Dennis-Beron
Sebastian Dennis-Beron
Current first- and second-line treatment options in acute promyelocytic leukemia [0.03%]
急性早幼粒细胞白血病的一线和二线治疗选择现状
Fulvio Massaro,Matteo Molica,Massimo Breccia
Fulvio Massaro
Outcome of acute promyelocytic leukemia (APL) has remarkably improved during the last 30 years, especially after the identification of PML-RARA oncogene as a key in the pathogenesis of APL and all-trans retinoic acid as therapeutic agent. A...
Trisenox: a paradigm shift in APL therapy, an interview with Francesco Lo-Coco [0.03%]
特рис诺克：急性早幼粒细胞白血病治疗领域的变革，对Francesco Lo-Coco的访谈
Francesco Lo-Coco
Francesco Lo-Coco
Francesco Lo-Coco speaks to Sebastian Dennis-Beron, Commissioning Editor: Francesco Lo-Coco is currently a full professor of hematology and head of the Laboratory of Integrated Diagnosis of Oncohematologic Diseases at the Department of Biom...
Management of multiple myeloma: the impact of ixazomib's approval in Canada [0.03%]
加拿大达雷妥尤单抗获批后的多发性骨髓瘤治疗现状及挑战
Donna E Reece
Donna E Reece
Donna E Reece speaks to Laura Dormer, Commissioning Editor: Dr Donna E Reece is a Professor of Medicine and Director of the Program for Multiple Myeloma and Related Diseases in the Department of Medical Oncology and Hematology at Princess M...
Agnieszka Korfel,Uwe Schlegel
Agnieszka Korfel